UCSF Pharmacogenetics of Membrane Transporters
Snp Publications
PMT SNP UID:3861
  1. Giacomet V, Nannini P, Vigano A, Erba P, Benincaso A, Bedogni G, Cattaneo D, Falvella FS, Zuccotti GV. Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study. Clin Drug Investig. 2015 May 27. PMID: 26013475.
  2. Wang Y, Tang L, Pan J, Li J, Zhang Q, Chen B. The recessive model of MRP2 G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: A systematic review and meta-analysis. Epilepsy Res. 2015 May;11256-63. PMID: 25847339.
  3. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2015 Apr 14. PMID: 25869015.
  4. Kim MG, Kim IW, Choi B, Han N, Yun HY, Park S, Oh JM. Population Pharmacokinetics of Cyclosporine in Hematopoietic Stem Cell Transplant Patients: Consideration of Genetic Polymorphisms. Ann Pharmacother. 2015 Mar 27. PMID: 25818517.
  5. Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer. 2015 Jan 22. PMID: 25611302.
  6. Pratt VM, Beyer BN, Koller DL, Skaar TC, Flockhart DA, Levy KD, Vance GH. Report of New Haplotype for ABCC2 Gene: rs17222723 and rs8187718 in cis. J Mol Diagn. 2014 Dec 29. PMID: 25554586.
  7. Meyer Zu Schwabedissen HE, Siegmund W, Kroemer HK, Rollnik JD. Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report. BMC Res Notes. 2014 Oct 3;7(1):688. PMID: 25280537.
  8. Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, Muwakkit SA. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014 Aug;24(8):387-96. PMID: 25007187.
  9. Au A, Baba AA, Azlan H, Norsa'adah B, Ankathil R. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients. J Clin Pharm Ther. 2014 Jul 24. PMID: 25060527.
  10. Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol. 2014 Jun;48(2):163-72. PMID: 24991206.
  11. Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J Antimicrob Chemother. 2014 Apr 30. PMID: 24788661.
  12. Werk AN, Bruckmueller H, Haenisch S, Cascorbi I. Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics. 2014 Apr 16. PMID: 24743544.
  13. Rädisch S, Dickens D, Lang T, Bonnett L, Arlanov R, Johnson MR, Schwab M, Marson AG, Pirmohamed M. A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine. Pharmacogenomics J. 2014 Feb 25. PMID: 24567120.
  14. Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z, Tian H, Xu A, Zhang J. Association of ABCC2 -24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia. PLoS One. 2014 Jan 3;9(1):e82681. PMID: 24404132.
  15. Burckart GJ, Figg WD 2nd, Brooks MM, Green DJ, Troutman SM, Ferrell R, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel D, Price DK, Sissung TM, Girnita DM, Zeevi A, Webber SA. Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. J Pediatr Pharmacol Ther. 2014 Jan;19(1):16-24. PMID: 24782687.
  16. Ulzurrun E, Stephens C, Ruiz-Cabello F, Robles-Diaz M, Saenz-López P, Hallal H, Soriano G, Roman E, Fernandez MC, Lucena MI, Andrade RJ. Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS One. 2014;9(4):e94675. PMID: 24732756.
  17. PLOS ONE staff. Correction: Association of ABCC2 -24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia. PLoS One. 2014;9(3):e91384. PMID: 24658099.
  18. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients. Clin Pharmacokinet. 2013 Apr 30. PMID: 23633119.
  19. Deng XY, Wang CX, Wang XD, Bi HC, Chen X, Li JL, Huang M. Genetic polymorphisms of UGT1A8, UGT1A9, UGT2B7 and ABCC2 in Chinese renal transplant recipients and a comparison with other ethnic populations. Pharmazie. 2013 Apr;68(4):240-4. PMID: 23700788.
  20. Grover S, Kukreti R. A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy. Epilepsia. 2013 Mar 18. PMID: 23506516.
  21. Sporis D, Bozina N, Basić S, Lovrić M, Babić T, Susak I, Marković I. Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Coll Antropol. 2013 Mar;37(1):41-5. PMID: 23697249.
  22. Subenthiran S, Abdullah NR, Joseph JP, Muniandy PK, Mok BT, Kee CC, Ismail Z, Mohamed Z. Linkage Disequilibrium between Polymorphisms of ABCB1 and ABCC2 to Predict the Treatment Outcome of Malaysians with Complex Partial Seizures on Treatment with Carbamazepine Mono-Therapy at the Kuala Lumpur Hospital. PLoS One. 2013;8(5):e64827. PMID: 23717663.
  23. Kim SH, Jee YK, Lee JH, Lee BH, Kim YS, Park JS, Kim SH. ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption. Allergy Asthma Immunol Res. 2012 Nov;4(6):362-6. PMID: 23115734.
  24. Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, Lechat P, Leblond V, Hulot JS. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2012 Oct 16. PMID: 23069858.
  25. Engström K, Ameer S, Bernaudat L, Drasch G, Baeuml J, Skerfving S, Bose-O'Reilly S, Broberg K. Polymorphisms in Genes Encoding Potential Mercury Transporters and Urine Mercury Concentrations in Populations Exposed to Mercury Vapor from Gold Mining. Environ Health Perspect. 2012 Oct 9. PMID: 23052037.
  26. Oh ES, Kim CO, Cho SK, Park MS, Chung JY. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet. 2012 Sep 25. PMID: 23007012.
  27. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2012 Aug 7. PMID: 22868256.
  28. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. 2012 Jun 5. PMID: 22664480.
  29. Grover S, Gourie-Devi M, Bala K, Sharma S, Kukreti R. Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs. Pharmacogenet Genomics. 2012 Jun;22(6):447-65. PMID: 22565165.
  30. Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, Tang Q, Zhou HH, Liu ZQ. ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients. CNS Neurosci Ther. 2012 May 28. PMID: 22630058.
  31. Campa D, Müller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer. 2012 Apr 2. PMID: 22473764.
  32. Deo AK, Prasad B, Balogh L, Lai Y, Unadkat JD. Inter-individual Variability in Hepatic Expression of the Multidrug Resistance-associated Protein 2 (MRP2/ABCC2): Quantification by LC/MS/MS. Drug Metab Dispos. 2012 Feb 8. PMID: 22318656.
  33. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel JD, Venzon D, Dahut B, Kohn EC, Kummar S, Yarchoan R, Giaccone G, Widemann BC, Figg WD. Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clin Cancer Res. 2012 Feb 3. PMID: 22307138.
  34. Hilger E, Reinthaler EM, Stogmann E, Hotzy C, Pataraia E, Baumgartner C, Zimprich A, Zimprich F. Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012 Jan;13(2):185-90. PMID: 22256867.
  35. Glass TR, Rotger M, Telenti A, Decosterd L, Csajka C, Bucher HC, Günthard HF, Rickenbach M, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Marzolini C, the Swiss HIV Cohort Study. Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS One. 2012;7(1):e29186. PMID: 22235271.
  36. Akiyama Y, Fujita KI, Ishida H, Sunakawa Y, Yamashita K, Kawara K, Miwa K, Saji S, Sasaki Y. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet. 2011 Dec 27. PMID: 22201120.
  37. Fang G, Zheng J, Yi-Jun D, Xiao-Yan Q, Jun-Jie D, Xiao-Jin S, Zhong-Dong L, Ming-Kang Z. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin Chim Acta. 2011 Dec 22. PMID: 22227166.
  38. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2011 Dec 20. PMID: 22186618.
  39. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A Pilot Study. Cancer. 2011 Sep 1. PMID: 21887680.
  40. Ufer M, von Stülpnagel C, Muhle H, Haenisch S, Remmler C, Majed A, Plischke H, Stephani U, Kluger G, Cascorbi I. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011 Jul 27. PMID: 21799461.
  41. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism. Clin Pharmacol Ther. 2011 Mar 30. PMID: 21451505.
  42. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L, Qiao R, Chen H, Wei Q, Wu J, Lu D. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer. 2010 Oct 11. PMID: 20943283.
  43. Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica. 2010 Sep 14. PMID: 20839930.
  44. Woillard JB, Rerolle JP, Picard N, Rousseau A, Drouet M, Munteanu E, Essig M, Marquet P, Le Meur Y. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol. 2010 Jun;69(6):675-83. PMID: 20565459.
  45. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2010 Mar 30. PMID: 20351751.
  46. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A, the Swiss HIV Cohort Study. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010 Feb 4. PMID: 20139798.
  47. Ohmann EL, Burckart GJ, Brooks MM, Chen Y, Pravica V, Girnita DM, Zeevi A, Webber SA. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant. 2010 Jan 8. PMID: 20061166.
  48. Zhang Y, Zhao T, Li W, Vore M. The 5'-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol Pharmacol. 2009 Nov 4. PMID: 19890061.
  49. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, Lu Z. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009 Jul 1. PMID: 19568750.
  50. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Häsler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009 May;19(5):353-62. PMID: 19415824.
  51. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics. J Clin Oncol. 2009 Apr 6. PMID: 19349540.
  52. Miura M, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta. 2009 Jan;399(1-2):83-7. PMID: 18838068.
  53. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y. Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI). Biol Pharm Bull. 2008 Nov;31(11):2137-42. PMID: 18981587.
  54. Zhang WX, Chen B, Jin Z, Yu Z, Wang X, Chen H, Mao A, Cai W. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica. 2008 Nov;38(11):1422-36. PMID: 18946804.
  55. Sookoian S, Castaño G, Gianotti TF, Gemma C, Pirola CJ. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J Nutr Biochem. 2008 Oct 14. PMID: 18926681.
  56. Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep;84(3):393-402. PMID: 18418374.
  57. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients. Ther Drug Monit. 2008 Aug 7. PMID: 18695635.
  58. Oswald S, König J, Lütjohann D, Giessmann T, Kroemer HK, Rimmbach C, Rosskopf D, Fromm MF, Siegmund W. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008 Jul;18(7):559-68. PMID: 18551036.
  59. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J Pharm Pharmacol. 2008 May;60(5):631-5. PMID: 18416940.
  60. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008 Apr;18(4):357-65. PMID: 18334920.
  61. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303. PMID: 18398970.
  62. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jan 21. PMID: 18221820.
  63. Sai K, Saito Y, Itoda M, Fukushima-Uesaka H, Nishimaki-Mogami T, Ozawa S, Maekawa K, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Matsumura Y, Ohtsu A, Saijo N, Sawada J. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet. 2008;23(2):139-47. PMID: 18445995.
  64. Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol. 2008 Jan;48(1):125-32. PMID: 17997497.
  65. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. PMID: 17906856.
  66. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007 Oct 10;25(29):4528-35. PMID: 17925548.
  67. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41. PMID: 17924828.
  68. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007 Jul 1;110(1):138-47. PMID: 17534875.
  69. Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, Chon CY, Han KH, Ahn SH, Jang IJ, Cho JY, Suh Y, Cho MO, Lee JE, Kim KH, Lee MG. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007 Jun;17(6):403-15. PMID: 17502832.
  70. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007 Feb;81(2):228-34. PMID: 17192769.
  71. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007 Feb;7(1):56-65. PMID: 16788565.
  72. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007 Jan;132(1):272-81. PMID: 17241877.
  73. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006 Nov;80(5):468-76. PMID: 17112803.
  74. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006 Oct 27;82(8):1074-84. PMID: 17060857.
  75. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9. PMID: 16791115.
  76. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Décosterd L, Telenti A, Swiss HIV Cohort Study. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics. 2005 Sep;15(9):599-608. PMID: 16041239.
  77. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos. 2005 Jul;33(7):896-904. PMID: 15821043.
  78. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, Lee EJ, Chowbay B. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005 Apr;59(4):415-24. PMID: 15801936.
  79. Jensen LE, Wall AM, Cook M, Hoess K, Thorn CF, Whitehead AS, Mitchell LE. A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida. Birth Defects Res A Clin Mol Teratol. 2004 Jun;70(6):396-9. PMID: 15211708.
  80. Nishioka C, Sakaeda T, Nakamura T, Moriya Y, Okamura N, Tamura T, Nakahara T, Aoyama N, Kamigaki T, Ohno M, Kuroda Y, Kasuga M, Okumura K. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci. 2004;50(5-6):181-8. PMID: 16107775.
  81. Shoda J, Suzuki H, Suzuki H, Sugiyama Y, Hirouchi M, Utsunomiya H, Oda K, Kawamoto T, Matsuzaki Y, Tanaka N. Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res. 2003 Dec;27(4):323-326. PMID: 14662121.
  82. Wakusawa S, Machida I, Suzuki S, Hayashi H, Yano M, Yoshioka K. Identification of a novel 2026G-->C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome. J Hum Genet. 2003;48(8):425-9. PMID: 12884082.
  83. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull. 2002 Oct;25(10):1356-9. PMID: 12392094.
  84. Itoda M, Saito Y, Soyama A, Saeki M, Murayama N, Ishida S, Sai K, Nagano M, Suzuki H, Sugiyama Y, Ozawa S, Sawada Ji J. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metab Dispos. 2002 Apr;30(4):363-4. PMID: 11901087.